SEC Filing Analysis: PFIZER INC (PFE)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Pfizer's Chairman & CEO, Albert Bourla, acquired 23 phantom stock units valued at approximately $608 as part of a non-discretionary deferred compensation plan.
• Market Impact: The transaction is entirely immaterial and has no market impact.

Company Information

Field	Value
Company	PFIZER INC
Ticker Symbol	PFE
CIK	0000078003
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	BOURLA ALBERT
CIK	0001595703
Title/Position	Chairman & CEO
Relationship	Director, Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-15
Transaction Code	A (Grant)
Security Type	Phantom Stock Units SSP
Shares Involved	23
Price Per Share	$26.43
Total Value	$607.89
Shares Owned After	742,986 (Derivative Units)
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$607.89
% of Market Cap	<0.00001%
Shares Transacted	23
% of Shares Outstanding	<0.00001%
Post-Transaction Ownership	742,986 derivative units (0.013% of outstanding shares)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of $608 is negligible for a company with a market capitalization of $142.48 billion.
• Ownership Concentration: The CEO's total derivative holdings represent a very small fraction (0.013%) of the total shares outstanding.
• Transaction Significance: This transaction is a routine, automated acquisition under a compensation plan, as indicated by the 'A' code and the footnotes. It carries no discretionary investment signal.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is automated, non-discretionary, and financially immaterial. It provides no new information to the market.

Volume & Sentiment

• Expected Volume Impact: None. The transaction is too small to have any effect on trading volume.
• Sentiment Indicator: Neutral. This filing is a routine administrative disclosure.

Additional Context

Transaction Notes

• Special Circumstances: The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. They are settled in cash upon separation from service.